Salubris released its 2026 interim report on August 25, 2026. Total operating revenue was 2.479 billion yuan, net profit attributable to the parent company was 387 million yuan, and net operating cash inflow was 466 million yuan. The company's latest asset-liability ratio was 21.52 percent, up 2.80 percentage points from the previous quarter and up 3.40 percentage points from the same period last year. The latest gross margin was 75.09 percent, down 1.49 percentage points from the previous quarter and down 0.22 percentage points from the same period last year. The latest return on equity was 4.52 percent, and diluted earnings per share was 0.35 yuan. The company's latest total asset turnover was 0.22 times, inventory turnover was 1.11 times, the number of shareholders was 74,100, and the top ten shareholders held 739 million shares, accounting for 66.25 percent of total share capital.
Shenzhen Salubris Pharmaceuticals Co LtdInterim report shows net profit of 387 million yuan, but no comparative figures or market expectations provided to judge positive or negative.